Alnylam Pharmaceuticals (ALNY) Operating Income (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Operating Income for 18 consecutive years, with $231.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Income rose 1528.74% year-over-year to $231.4 million; the trailing twelve-month figure through Jun 2026 stood at $999.8 million (up 654.86% YoY), and the FY2025 full-year result was $501.6 million, up 383.56% from the prior year.
• Operating Income eased to $231.4 million in Q2 2026 per ALNY's latest filing, from $268.6 million in the prior quarter.
• Across five years, Operating Income topped out at $368.0 million in Q3 2025 and bottomed at -$258.0 million in Q3 2022.
• Historically, Operating Income has averaged -$13.5 million across 5 years, with a median of -$60.2 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Operating Income slumped 135.96% in 2024, then jumped 1528.74% in 2026.
• Over 5 years, Operating Income stood at -$188.6 million in 2022, then soared by 38.28% to -$116.4 million in 2023, then increased by 9.66% to -$105.2 million in 2024, then surged by 225.26% to $131.7 million in 2025, then soared by 75.71% to $231.4 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered $231.4 million, $268.6 million, and $131.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.